Skip to content
MarketScale
‹ Back to IndustriesSciences

Composite Use is Improving Public Rail Transportation

Composites are increasingly being used in the transportation industry due to an expanding emphasis on finding materials that are lighter, stronger and with the ability to withstand a wide variety of harsh conditions. This unique combination of properties makes composites ideal for improving the efficiency of rail transportation for many reasons, and MVP can help…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
Composite Use is Improving Public Rail Transportation

Key takeaways

01

Composites are increasingly being used in the transportation industry due to an expanding emphasis on finding materials that are lighter, stronger and with the ability to withstand a wide variety of harsh conditions.

02

This unique combination of properties makes composites ideal for improving the efficiency of rail transportation for many reasons, and MVP can help…

Composites are increasingly being used in the transportation industry due to an expanding emphasis on finding materials that are lighter, stronger and with the ability to withstand a wide variety of harsh conditions. This unique combination of properties makes composites ideal for improving the efficiency of rail transportation for many reasons, and MVP can help this industry and more with the application of these materials.

The Pressure to Lighten the Load and Improve Aerodynamics

Rising fuel costs have resulted in even greater demand for weight reduction and sleeker aerodynamics, putting rail manufacturers on track for extensive use of these materials in equal measure. High speed commuter trains also have a tremendous impact on the rail system itself. As François Lacôte, Senior Vice President, Technical Department of French manufacturer Alstom, puts it, “The higher the speed, the heavier the impact on infrastructure.”

The Benefits of Composites in Rail Applications

Composites offer many benefits for rail applications. Primarily, composites offer high strength/ high stiffness to weight ratios, resulting in lighter trains without sacrificing durability and performance. In addition, their low thermal conductivity delivers further savings due to decreased energy consumption by air conditioning systems. Composites also deliver excellent corrosion resistance, which can improve service life and reduce maintenance costs. Additionally, composites lower vibration and noise level, creating a better passenger experience. Finally, by reducing the number of parts required, composites decrease complexity for manufacturers, allowing for easier fabrication.

Composites Can Be Used Throughout Railcars for Improved Operations

The most obvious use for composites is on a train’s exterior panels and superstructure, such as aerodynamically contoured composite front ends, or “noses”, which are used to reduce air resistance and will, therefore, increase fuel efficiency in high-speed trains. However, in the very near future, these materials will be increasingly used on primary structures and mechanical components as well. In fact, the use of composites for complex air inlet shapes and curvatures that alleviate aerodynamic noise when drawing in outside air is already being adopted.

Composites can also be used for interior trims such as window and door frames, and for furniture and fixtures, including side panels, roof panels, doors, and flooring. Even durable, easy-to-install modular toilets are gaining popularity for use on passenger trains. It’s apparent that every application provides another opportunity for weight and cost savings through the use of composites.

Magnum Venus Products Can Help with Composite Application Equipment for Rail

Magnum Venus Products (MVP) is the premier manufacturer of composite application equipment including pumping systems, spray guns, filament winding systems and much more. MVP is proud to serve manufacturers in rail systems, as well as a variety of other industries including automotive, aerospace, oil & gas, and wind turbines, to name just a few.

MVP. Customer Focused. Product Driven.

To connect with an MVP distributor in your country, visit http://www.mvpind.com/mvp-international/.

Read more at

mvpind.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512